Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Launched by ISTITUTO ROMAGNOLO PER LO STUDIO DEI TUMORI DINO AMADORI IRST S.R.L. IRCCS · Jun 10, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on understanding the experiences of patients with acute myeloid leukemia (AML) who have either relapsed (the cancer returned after treatment) or are refractory (the cancer did not respond to treatment). The study aims to gather information from patients across different clinical sites, helping researchers learn more about the disease and how it affects patients.

To be eligible for this study, participants must have a confirmed diagnosis of AML and have experienced treatment failure, meaning their cancer either returned or did not respond to previous treatments. Patients of all genders aged 21 and older can participate if they or their legal representatives are willing to provide informed consent. Since this is an observational study, participants won't be receiving any new treatments but will help researchers by sharing their experiences and outcomes. This valuable information could help improve future treatments for AML.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with AML diagnosis according to WHO2022 or ICC2022
• • Treatment failure (i.e. relapse, refractory or progression, including MRD) according to ELN2022 criteria
• • Participant or his/her legal representative is willing and able to give informed consent for participation in the study
• Exclusion Criteria:
• • Patients included in clinical trials may be enrolled except where otherwise specified in the experimental protocol.